Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
 
Survey
We asked 50 leaders, Which of the following business challenge poses the greatest
threat to your company?

Building a sustainable product pipeline 47%
Attracting a skilled workforce 13%
Regulatory compliance 40%

Talk to us:
jupton@advanstar.com

Advertise with us:
wblow@advanstar.com

29 April, 2014
Market Access for Specialty Products in Latin America
Andrea Sobrio and Dr. Sandra Schoenes examine the market access challenges and opportunities specifically for premium, specialty inpatient products in the LatAm region ...Read more
The ‘Real’ Cost Effectiveness Threshold in England
In England, there has been a huge effort to work out the ‘real’ cost effectiveness ratio. But instead of looking at what society might be willing to pay for a Quality Adjusted Life Year (QALY), researchers from the Centre for Health Economics, OHE and Imperial College, London, have looked at what local health agencies actually spent by disease and what this buys them ... Read more
The Future of Pharma: Assessing the Drivers of Change
Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines ... Read more
Read April’s Pharm Exec Emerging Markets Special
In this issue: Africa — factors affecting direct foreign investment in the healthcare sector; Diabetes in China — is pharma listening to social media?; HIV treatments in Russia — dynamics, challenges, recommendations; Latin America — market access for specialty products; and more ... Read more
Product Profiles
Sciformix
Scignal Plus: Taking the Noise Out of Signal Detection
Scignal Plus provides superior, efficient signal detection by incorporating computational algorithms for a new method and previously known methods of signal detection. It has several distinct and important advantages over other products that are available in the market. Read more.
Also in this issue
New Wave of Pancreatic Cancer Drugs’ Revenue Potential “Limited”
Regional Trends in US Bioinvestment
Fixing Wikipedia